Drug Database
ME

meningococcal meningitis conjugate vaccine (Muinexi / CRM197 / MCV AC)

✓ Approved

CanSino Biologics · Cell-based Therapies · Cell-based Therapies

What is meningococcal meningitis conjugate vaccine?

meningococcal meningitis conjugate vaccine is a cell-based therapies developed by CanSino Biologics. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesMuinexi, CRM197, MCV AC
CompanyCanSino Biologics
Drug ClassCell-based Therapies, Vaccine
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, CanSino Biologics

Therapeutic Indications

meningococcal meningitis conjugate vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeningococcal bacteraemia✓ Approved

Related Research Articles

PubMedAdvances in virology2026-09-20

Comparative Sequence Analysis of the Envelope Gene of Kyasanur Forest Disease Virus Vaccine Strain With Currently Circulating Field Strains.

Kaje Keerthi K, Marinaik Chandranaik B CB, Gomes Amitha Reena AR, Rizwan Apsana A et al.

The present study was undertaken with the objective of performing comparative sequence analysis of the envelope (E) gene of Kyasanur forest disease virus (KFDV) vaccine strain P9605 with the circulating field strains. The study was taken up as the currently used KFDV vaccine strain, KFDV P9605, was isolated in the 1960s. For this study, we designed two sets of primers targeting the complete amplification of the E gene of KFDV. The sequencing was performed by the Sanger method, and the deduced sequence of the vaccine virus was deposited in GenBank with accession number PX067005. This sequence obtained for the vaccine virus was aligned and compared with sequences of GenBank-deposited circulating field strains. We also performed comparative sequence analysis of the Kyasanur forest disease (KFD) vaccine seed virus having passaged twice in mouse brain with the vaccine seed virus passaged six times in mouse brain to investigate whether multiple passages in mouse brain will lead to genetic mutation in the immunologically important E gene. The phylogenetic analysis revealed seven amino acid mutations in the field strains at positions A123T, S158N, D178E, D239N, A313S, M429I, and G479A when compared with the vaccine strain. We did not find any mutations at the critical fusogenic segment (residues 98-113) in the E gene of currently circulating field strains compared to the vaccine seed virus. The study found no genetic variations in the E gene of the KFD virus passed two times and passed six times in mouse brain. We performed SWISS-MODEL homology modeling, AlphaFold protein analysis, and Ramachandran plot analysis to study the E protein structures and stability. The observations made in this study suggest slow evolutionary drift and conserved structural stability of the envelope gene of KFDV ever since its emergence 7 decades ago; however, the functional implications of these amino acid substitutions need further studies on their roles in viral infectivity, transmission, and impact on immunity.

PMID 42763584
Read full article →
PubMedInternational journal of nanomedicine2026-09-20

Biotinylated ε-Polylysine-Cyclodextrin-Coated Mesoporous Silica Nanoparticles for Targeted pH-Responsive Baicalin Delivery.

Liao Rongqiang R, Ruan Yi Y, Zhang Ke K, Liu Maoxia M

Baicalin (BAI) is a natural flavonoid with antitumor potential, but its poor water solubility and low bioavailability limit clinical use. Mesoporous silica nanoparticles are promising drug carriers due to their large surface area and tunable pore structure, yet premature drug leakage remains a key challenge. A multifunctional nanoplatform, designated as BPCD@BAI@BMSN, was constructed to enable efficient baicalin loading, pH-responsive gated release, and biotin-mediated active tumor targeting. A novel biotin-ε-polylysine-cyclodextrin (BPCD) conjugate was synthesized via EDCI/NHS coupling and characterized by NMR and GPC. Hollow mesoporous silica nanoparticles (BMSN) were prepared by the Stöber method, surface-modified with benzothiazole. The BPCD conjugate was coated onto the nanoparticle surface via cyclodextrin-benzothiazole host-guest self-assembly. The resulting nanoparticles were characterized by TEM, DLS, zeta potential, FTIR, and TGA. Drug loading, pH-responsive release, cytotoxicity against SMMC-7721 cells, cellular uptake evaluated by confocal microscopy and flow cytometry, and in vivo antitumor efficacy in nude mice were systematically evaluated. BPCD@BAI@BMSN exhibited near-spherical morphology with a particle size of approximately 200 nm, a positive zeta potential of +10 mV, a drug loading of 19.85%, and an encapsulation efficiency of 89.6%. Cumulative baicalin release reached approximately 62% at pH 5.5, whereas only about 6% was released at pH 7.4, confirming acid-triggered gated release. The blank carrier showed no significant cytotoxicity with cell viability above 95%, while drug-loaded nanoparticles exhibited enhanced cytotoxicity at pH 6.8. Biotin-functionalized nanoparticles demonstrated significantly higher cellular uptake and tumor accumulation compared to non-targeted controls. In vivo, BPCD@BAI@BMSN achieved a tumor growth inhibition rate of 72.5% compared to the control group, with no obvious toxicity to major organs observed during the 21-day treatment period. BPCD@BAI@BMSN integrates high drug loading, pH-responsive supramolecular gating, and active tumor targeting into a single nanoplatform, offering a promising strategy for baicalin delivery with enhanced antitumor efficacy and favorable short-term biosafety.

PMID 42763689
Read full article →
PubMedCureus2026-09-20

Beyond the Usual Pathogens: Community-Acquired Meningoencephalitis Caused by Streptococcus equi in an Immunocompetent Adult.

Hammadi Hicham H, Elbouti Anas A, Chikhi Brahim B, Aarjouni Youssef Y et al.

Streptococcus equi is a rare zoonotic pathogen that only occasionally causes invasive central nervous system infections in humans. We report the case of a previously healthy 50-year-old man who presented with fever and altered mental status in the setting of recent animal exposure. Cerebrospinal fluid analysis was consistent with acute bacterial meningitis, while direct microscopy and multiplex polymerase chain reaction identified S. equi. Antimicrobial susceptibility testing confirmed susceptibility to ceftriaxone. Despite early initiation of intravenous ceftriaxone and adjunctive dexamethasone, the patient's course was complicated by generalized status epilepticus requiring intensive care support. He subsequently showed progressive neurological recovery with a favorable outcome. This case underscores the importance of considering S. equi as a potential cause of community-acquired bacterial meningoencephalitis in patients with relevant zoonotic exposure and highlights the value of rapid molecular diagnostics for early pathogen identification and targeted antimicrobial therapy.

PMID 42763617
Read full article →
PubMedEarth, planets, and space : EPS2026-09-20

Estimation of auroral emission altitude in the region of the ISS magnetic footprint during a relativistic electron precipitation event observed by ISS-CALET.

Yanagisawa Kyutaro K, Kataoka Ryuho R, Seki Kanako K, Whiter Daniel D et al.

We report a multi-MeV relativistic electron precipitation (REP) event as observed by the CALorimetric Electron Telescope and the Monitor of All-sky X-ray Image aboard the International Space Station, together with low-cost twin all-sky auroral imagers installed at Athabasca, Canada. We find that visible auroral emissions near the ISS magnetic footprint during REP events are not frequent-observed in only two of 10 conjugate REP events during our survey period from September 2024 to September 2025-and that one case, on 3 May 2025, featured diffuse aurora near the ISS magnetic footprint. Using two independent stereoscopic methods, we estimate the auroral emission height to be ~90 km, which is typically produced by tens-of-keV electron precipitation. Combined with the MeV electron precipitation detected by CALET, such broadband electron precipitation from tens-of-keV to MeV is consistent with the hypothesis of chorus-driven REP events. The emission altitude shows no systematic latitudinal variation, which is not consistent with field-line curvature scattering type energy-dispersed precipitation. The combined space- and ground-based observations contribute to a better understanding of the spatial context of wave-particle interaction associated with the REP events.

PMID 42763453
Read full article →
PubMedJournal of medical case reports2026-09-19

Like father, like daughter: amoxicillin-induced aseptic meningitis in a female patient and her father: a case report.

Farhood Ibrahim I, Seidel Sabine S, Kaeder Maximilian M, Schönlau Lars L et al.

Drug-induced aseptic meningitis (DIAM) is a neurological disorder that requires specialized diagnostic pathways and an in-depth patient history to prevent inaccurate diagnoses and unnecessary procedures. Amoxicillin has been reported as one of the drugs causing recurrent DIAM, with a total of 22 patients described in the literature. We report two cases involving patients of Mediterranean ethnicity -a father (69-years-old) and his daughter (47-years-old)-who presented to our neurology department at different time points with severe headache persisting for several days. Both patients disclosed recent use of amoxicillin to treat bronchitis and otitis. In both cases, examination of cerebrospinal fluid (CSF) revealed leukocytosis with lymphocytic predominance, while no causative pathogens were identified. After extensive investigations to rule out other causes of secondary headache, a diagnosis of amoxicillin-induced aseptic meningitis (AIAM) was established. Notably, the daughter experienced two similar episodes, both temporally associated with amoxicillin intake. Amoxicillin-induced aseptic meningitis is a rare adverse reaction that should be considered in patients presenting with severe headache in the absence of an identifiable pathogen. A thorough patient history combined with comprehensive diagnostic evaluation is essential to establish the diagnosis and to avoid unnecessary or excessive treatment. Additionally, potential genetic predispositions, as suggested in other forms of drug-induced aseptic meningitis, may play a role and should be considered in selected cases.

PMID 42760564
Read full article →
PubMedInfection and drug resistance2026-09-19

Refractory Bacterial Meningitis Associated with an Occult Posterior Fossa Dermal Sinus Tract in an Infant: A Case Report.

Zhuang Rong R, Liang Chao C, Jin Jia-Ping JP, Jin Bo B et al.

Posterior fossa dermal sinus tracts are extremely rare congenital lesions that may extend intracranially and communicate with the dura or brain tissue. This abnormal connection can provide a persistent route for bacterial entry into the central nervous system, predisposing patients to severe infections such as meningitis. We report the case of a 1-year-old boy with refractory bacterial meningitis that remained unresponsive to prolonged broad-spectrum antibiotic treatment. MRI revealed an occult posterior fossa lesion, and cerebrospinal fluid NGS detected multiple microorganisms of uncertain clinical significance, none of which was considered the definitive causative pathogen. Intraoperatively, a sinus tract was found communicating with an intracranial cystic lesion, subsequently confirmed as an infected dermoid cyst on histopathology. After surgical excision and postoperative intraventricular antimicrobial therapy, the patient showed sustained improvement with no recurrence at 6-month follow-up. This case suggests that an occult posterior fossa dermal sinus tract may represent an underrecognized anatomical source of treatment-resistant meningitis and highlights the importance of early structural evaluation when standard antimicrobial therapy fails. Timely surgical intervention may be important for source control and prevention of recurrence.

PMID 42761913
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about meningococcal meningitis conjugate vaccine